lactoferrin and Parkinsonian-Disorders

Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease. Its pathological features are dopaminergic neuronal death in the substantia nigra (SN), and significant reduction in dopamine (DA) content in the striatum. A large number of studies have found an increase in iron levels in PD patients and animal models, which suggested that brain iron metabolism dysfunction played a key role in the pathogenesis of PD. Lactoferrin (Lf) is a non-heme iron-binding glycoprotein belonging to the transferrin family, entering the cell membrane via a lactoferrin receptor-mediated pathway. Lf exists mainly in two forms: iron-free-lactoferrin (apo-Lf) and iron-saturated-lactoferrin (holo-Lf). Our previous studies found thatapo-Lf and holo-Lf exert neuroprotective effects against 1-methyl-4-phenylpyridinium toxicity in ventral mesencephalon neurons in vitro. This study aimed to further investigate whether two different forms of Lf have neuroprotective effects in vivo, and to examine their mechanisms, so as to provide an experimental basis for finding new therapeutic strategies against PD. In the central nervous system, Lf antagonized 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced DA depletion in the striatum, iron deposition, oxidative, and apoptotic processes in the SN. Lf treatment down-regulated iron import protein divalent metal transporter1 and up-regulated iron export protein ferroportin1, attenuating MPTP-induced accumulation of nigral iron level. In the peripheral system, Lf alleviated MPTP-induced increases in serum iron and ferritin, and decreases in serum total iron-binding capacity, loss of spleen weight, and reduction in spleen iron content. The results indicate that Lf has a neuroprotective effect on MPTP-induced PD model mice, and its mechanism may be related to anti-iron dysregulation, anti-oxidative stress, and anti-apoptosis, with apo-Lf showing greater efficacy. Therefore, Lf might be a promising therapeutic substance for PD. Open Science: This manuscript was awarded with the Open Materials Badge For more information see: https://cos.io/our-services/open-science-badges/.

Topics: Animals; Apoptosis; Iron; Lactoferrin; Male; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Substantia Nigra

Gene therapy is considered one of the most promising approaches to develop an effective treatment for Parkinson's disease (PD). The existence of blood-brain barrier (BBB) significantly limits its development. In this study, lactoferrin (Lf)-modified nanoparticles (NPs) were used as a potential non-viral gene vector due to its brain-targeting and BBB-crossing ability.. The neuroprotective effects were examined in a rotenone-induced chronic rat model of PD after treatment with NPs encapsulating human glial cell line-derived neurotrophic factor gene (hGDNF) via a regimen of multiple dosing intravenous administration. The results showed that multiple injections of Lf-modified NPs obtained higher GDNF expression and this gene expression was maintained for a longer time than the one with a single injection. Multiple dosing intravenous administration of Lf-modified NPs could significantly improve locomotor activity, reduce dopaminergic neuronal loss, and enhance monoamine neurotransmitter levels on rotenone-induced PD rats, which indicates its powerful neuroprotective effects.. The findings may have implications for long-term non-invasive gene therapy for neurodegenerative diseases in general.

Topics: Animals; Chronic Disease; Disease Models, Animal; Gene Expression Regulation; Gene Transfer Techniques; Genes, Reporter; Genetic Therapy; Genetic Vectors; Glial Cell Line-Derived Neurotrophic Factor; Green Fluorescent Proteins; Lactoferrin; Male; Nanoparticles; Neurotoxins; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Treatment Outcome; Uncoupling Agents

The presence of the iron-binding protein lactoferrin (Lf) in some specific areas of the central nervous system and particularly in the normal human substantia nigra, where it is found in dopaminergic (DA) neurons and some glial cells, led us to investigate Lf synthesis in this area. Lf mRNA were identified using in situ hybridization and found in small ameboid cells. These cells were identified using immunocytochemistry as activated microglia since they exhibited macrophage markers such as the CD68 and the CR1 antigens. Double immunofluorescent labeling confirmed that the two Lf immunostained cell populations were activated microglia and DA neurons. Since activated microglia contained both Lf and its messenger, these cells are the Lf producing cells. The presence of Lf in DA neurons in which no Lf messengers were visible, might be due to an endocytosis mechanism, DA neurons probably internalizing Lf produced in microglial cells located in their neighborhood. In neuropathological disorders, such as Alzheimer's and Parkinson's diseases, inflammatory process and oxidative stress are events that contribute to neuronal death. Since Lf concentration increases during these pathologies, we studied the level of Lf expression under these different stresses and showed, using RT-PCR, that the immortalized human embryonic microglial CHME cell line produced Lf transcripts under tumor necrosis factor alpha or 1-methyl-4-phenylpyridinium treatment whereas untreated cells did not. These data confirm that Lf is produced only when microglia are activated.

Topics: 1-Methyl-4-phenylpyridinium; Aged; Antineoplastic Agents; Cell Line, Transformed; Encephalitis; Female; Gene Expression; Humans; Lactoferrin; Male; Microglia; Oxidative Stress; Parkinsonian Disorders; Polymerase Chain Reaction; RNA, Messenger; Substantia Nigra; Tumor Necrosis Factor-alpha